Kura Oncology is trading at $6.80, down 10.58%, amid a sharp broader-market sell-off and biotech weakness. - XBI fell 5.19% during the regular session. - Reuters reported steep technology-stock losses amid investor concerns about AI spending and data-center scrutiny, consistent with the risk-off backdrop. - A headline temporally linked Kura’s decline to J&J blood-cancer data, but coverage provides no details or confirmed causal explanation; no clear company-specific announcement explains the move.